Myeloma Paper of the Day, November 16th, suggested by Robert Orlowski
Robert Orlowski shared a post on X:
“Myeloma Paper of the Day: IFM 2014-01 study of Ixazomib/pom/dex in relapsed/refractory myeloma finds median TTP 10.2 months and median OS was 23.7, with interesting activity against high-risk t(4;14).”
Authors: Arthur Bobin, Salomon Manier, Joe De Keizer, Jaydeep K Srimani, Cyrille Hulin, Lionel Karlin, Denis Caillot, Ingrid Lafon, Clara Mariette, Carla Araujo, Bertrand Arnulf, Benoît Bareau, Karim Belhadj, Lofti Benboubker, Thorsten Braun, Claire Calmettes, Olivier Decaux, Mamoun Dib, Hélène Demarquette, Caroline Jacquet, Cécile Sonntag, Sophie Godet, Arnaud Jaccard, Pascal Lenain, Margaret Macro, Valentine Richez-Olivier, Mourad Tiab, Laure Vincent, Hacene Zerazhi, Marie-Odile Pétillon, Sandrine Rollet, Helene Gardeney, Geraldine Durand, Anthony Levy, Cyrille Touzeau, Aurore Perrot, Philippe Moreau, Thierry Facon, Jill Corre, Stephanie Ragot, Herve Avet-Loiseau, Xavier Leleu.
More posts featuring Robert Orlowski.
Robert Orlowski, M.D., Ph.D., holds multiple positions at The University of Texas MD Anderson Cancer Center, including Chairman, Ad Interim Director of Myeloma, and Professor of Medicine in the Departments of Lymphoma/Myeloma and Experimental Therapeutics within the Division of Cancer Medicine. Additionally, he chairs the SWOG Barlogie/Salmon Myeloma Committee, which is part of the National Clinical Trials Network, dedicated to advancing new therapies and understanding the biology of myeloma.
Dr. Orlowski’s expertise lies in both clinical practice and scientific research, with a particular focus on translating laboratory discoveries into effective treatments for patients. He investigates drug resistance mechanisms in myeloma and seeks to identify predictive biomarkers for treatment response. Notably, his past contributions include leadership roles in developing proteasome inhibitors like bortezomib and carfilzomib, as well as monoclonal antibodies such as daratumumab and elotuzumab.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023